THE COST-EFFECTIVENESS OF AN EXTENDED COURSE (12+12 WEEKS) OF VARENICLINE PLUS BRIEF COUNSELLING COMPARED WITH OTHER REIMBURSED SMOKING CESSATION INTERVENTIONS IN BELGIUM, FROM A PUBLIC PAYER PERSPECTIVE

Objective: To evaluate the cost-effectiveness of an extended (12+12 weeks) course of varenicline plus brief counselling compared with the currently reimbursed smoking cessation interventions (in combination with brief counselling) in Belgium, from a public payer perspective. Methods: The previously published version of the BENESCO model which included the extended course of varenicline was updated with recent publically available demographic and cost data from Belgium. Results: The extended course of varenicline plus brief counselling has an incremental cost per quality adjusted life year gained of 1101(sic) compared with a non-extended 12-week course of varenicline (plus brief counselling). The extended course of varenicline dominates all other comparators in this analysis. Conclusions: The extended course of varenicline (12 weeks followed by 12 weeks maintenance therapy in successful quitters) plus brief counselling is a highly cost-effective alternative to a non-extended (12 weeks only) course of varenicline plus brief counselling. This strategy dominates the other alternative smoking cessation interventions currently reimbursed in Belgium.